New to peptides? Start with the foundations ->
The dad-test answer
GI side effects (nausea, vomiting, constipation, diarrhea) are the dominant issue with both molecules - they happen during dose escalation and usually fade. In SURMOUNT-5 head-to-head, gastrointestinal events causing treatment discontinuation were higher on semaglutide (5.6%) than tirzepatide (2.7%). In broader meta-analyses, tirzepatide has slightly higher overall GI event rates but a lower discontinuation rate. Neither molecule is friendly during the titration phase; both are usually tolerable at maintenance.
Who wins for what
| Use case | Who wins, and why |
|---|---|
| lower discontinuation due to GI side effects |
tirzepatide SURMOUNT-5: 2.7% discontinued tirzepatide for GI vs 5.6% on semaglutide over 72 weeks. |
| lower overall GI event rate |
semaglutide Meta-analysis (Ann Saudi Med 2025): tirzepatide RR 2.94 vs semaglutide RR 1.68 vs placebo for GI events overall - though most cases are mild. |
| first-time injectable, sensitive stomach |
semaglutide Lower peak nausea intensity in patient-reported outcomes; longer real-world experience guiding dose-escalation pacing. |
| extended titration tolerability |
tirzepatide Five-step titration over 20+ weeks gives the gut time to adapt; SURMOUNT data shows the 'tirzepatide is harder' story is overstated when titration is paced. |
What the head-to-head data shows
SURMOUNT-5 (Aronne et al., NEJM 2025) is the head-to-head: 751 adults randomized to maximum-tolerated tirzepatide or maximum-tolerated semaglutide for 72 weeks. GI adverse events were the most common in both arms, mostly mild-to-moderate, mostly during dose escalation. Discontinuation for GI causes was 2.7% on tirzepatide vs 5.6% on semaglutide - notable because the popular narrative is the reverse. Patel et al. 2024 analyzed GI events across SURPASS trials in Type 2 diabetes; Rubino et al. 2025 covered SURMOUNT-1 to -4. Meta-analytic data shows tirzepatide has a higher overall GI event rate vs placebo (RR ~2.94) than semaglutide (RR ~1.68), but discontinuation rates run lower on tirzepatide because the events are usually mild and titration-paced. Both molecules carry the standard GLP-1 black-box warning for thyroid C-cell tumors (rodent data), and post-market surveillance has flagged rare cases of pancreatitis, gallbladder disease, and ileus on both.
Our honest call
The popular framing - tirzepatide is harder on the gut - isn't what the head-to-head data actually shows. In SURMOUNT-5, more patients quit semaglutide for GI reasons than tirzepatide. The pragmatic read: at the standard dose-escalation cadence, both molecules are roughly equivalent in real-world tolerability, with most users hitting peak nausea during weeks 4-8 and adapting by month 3. Patients with severe pre-existing GI conditions (gastroparesis, recurrent pancreatitis, severe GERD) should not start either without specialist sign-off. The most consistent advice from prescribers we trust: titrate slowly, eat smaller portions earlier in the day, hydrate aggressively, and don't be a hero on the dose ladder. Read the GLP-1 starter guide for the titration playbook and the main efficacy comparison for weight-loss and A1C side.
Sources and citations
- Aronne et al., SURMOUNT-5 head-to-head trial, NEJM 2025 (PMID 40374016)
- Patel et al., SURPASS GI tolerability analysis, Diabetes Obes Metab 2024
- Rubino et al., SURMOUNT-1 to -4 GI tolerability, Diabetes Obes Metab 2025
- FDA Zepbound prescribing label (approved Nov 2023)
- FDA Wegovy prescribing label (approved Jun 2021)
Where to go next
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.
Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine. None of this replaces a doctor. Peptides are gray-market in the US for most uses. Talk to a real prescriber before you change anything.